Genmab A/S (NASDAQ:GMAB) Shares Gap Up – Still a Buy?

Shares of Genmab A/S (NASDAQ:GMAB) gapped up prior to trading on Thursday . The stock had previously closed at $20.23, but opened at $20.93. Genmab A/S shares last traded at $20.84, with a volume of 112,594 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have commented on GMAB. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, January 8th. Redburn Atlantic assumed coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

The firm has a 50 day moving average of $21.15 and a two-hundred day moving average of $24.07. The stock has a market cap of $13.76 billion, a PE ratio of 20.19, a PEG ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period last year, the company earned $0.47 earnings per share. As a group, equities analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares in the last quarter. Blue Trust Inc. grew its stake in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in shares of Genmab A/S in the third quarter worth $192,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.